SC 13G - Skye Bioscience, Inc. (0001516551) (Subject)

SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that the company's third quarter 2024 financial results will be released after market close on Thursday, November 7, 2024. Skye will host a conference call to discuss its results at 1:30 p.m. PT/4:30 p.m. ET. The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Following the call, a replay and transcript will be available at the same website.

SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the Board has appointed independent director Paul Grayson as Skye's new Chairman of the Board, effective October 25, 2024. Mr. Grayson currently serves as a member of Skye's Audit, Compensation and Nominating and Corporate Governance Committees. Punit Dhillon, Skye's Chief Executive Officer, will continue to serve as a member of the Board. Punit Dhillon, Skye's Chief Executive Officer and former Chairman of the Board, commented, "We have a high bar with respect to how

SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that it will participate in the following upcoming healthcare investment conferences: Guggenheim Healthcare Conference (Boston) Presentation, Monday, November 11, 1:00 pm ET + 1x1 meetings UBS Healthcare Conference (Rancho Palos Verdes) Fireside chat, Wednesday, November 13, 12:30 pm PT + 1x1 meetings Stifel Healthcare Conference (New York) Presentation, Tuesday, November 19, 3:00 pm ET + 1x1 meetings Craig-Hallum Alpha Select Conference (New York)

16-week top-line weight loss data validates mechanism of action targeting peripheral CB1 receptors Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule approach SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on developing new therapeutics for metabolic health, is providing a statement regarding a recent announcement by Novo Nordisk on Phase 2a top-line data with monlunabant, Novo's small-molecule oral cannabinoid receptor (CB1) inverse agonist. "We are encouraged to see that monlunabant met its primary endpoint and demonstrated at least a 6% placebo-ad

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the appointment of Puneet S. Arora, MD, MS, FACE, as Chief Medical Officer (CMO). "We are thrilled to welcome Dr. Puneet Arora as the Chief Medical Officer at Skye at this pivotal moment in our journey, particularly with the initiation of the Phase 2 CBeyond™ obesity clinical trial for nimacimab, our differentiated CB1 inhibitor," said Punit Dhillon, Skye's CEO and Chair. "Dr. Arora is well-regarded in the industry, brings extensive experience in designing and executing cli

SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that it will participate in the following upcoming healthcare investment conferences: Morgan Stanley, Friday, September 6, 1x1 meetings (New York)Cantor Global Healthcare Conference, Thursday, September 19, 8:35 am ET, presentation + 1x1 meetings (New York)Bank of America World Medical Innovation Forum, Tuesday, September 24, panel + 1x1 meetings (Boston) Available webcasts will be accessible on Skye's website. About Skye Bioscience Skye i

SAN DIEGO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on August 22, 2024, the Board of Directors granted a non-qualified stock option award to purchase 40,000 shares of its common stock to one new non-executive employee under the Company's 2024 Inducement Equity Incentive Plan (the "2024 Inducement Plan"). The stock options were granted as an inducement material to the employee entering into employment with Skye in accordance with Nasdaq Listing Rule 5635(c)(4). The 2024 Inducement Plan is used exclusively for the grant of

SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, has started screening patients for a Phase 2 clinical trial (CBeyondTM) of its novel peripheral CB1 inhibitor, nimacimab, a negative allosteric modulating antibody. The study will assess the ability of nimacimab as a next-generation weight loss therapeutic to safely and effectively reduce weight in patients with obesity. It will assess parameters increasingly viewed as important to the long-term quality and/or sustainability of weight loss, including gastrointestinal tolerability (GI) and le

SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate achievements. "Our strategic acquisition of nimacimab in August 2023 has propelled Skye into the metabolic landscape, where there is a need to provide patients with obesity more tolerable and sustainable therapeutic alternatives to manage weight loss and address comorbid conditions," said Punit Dhillon, CEO of Skye. "In Q2, at our event, ‘Metabolic Rewiring wi

BOSTON and SAN DIEGO, July 24, 2024 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leader in at-home sleep monitoring and computational neurodiagnostics, today announced a strategic collaboration with Skye Bioscience, Inc. (NASDAQ:SKYE), a pharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, to enhance its upcoming CBEYOND™ Phase 2 clinical trial of Nimacimab. This partnership will incorporate sleep quality and sleep apnea endpoints via the Beacon Platform and the FDA 510(k)-cleared Dreem 3S EEG device to better understand the comprehensive impact of Nimacimab on patients with obesity. Nimacimab, a negative allosteric-modulating antibody that inhibits the

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the appointment of Puneet S. Arora, MD, MS, FACE, as Chief Medical Officer (CMO). "We are thrilled to welcome Dr. Puneet Arora as the Chief Medical Officer at Skye at this pivotal moment in our journey, particularly with the initiation of the Phase 2 CBeyond™ obesity clinical trial for nimacimab, our differentiated CB1 inhibitor," said Punit Dhillon, Skye's CEO and Chair. "Dr. Arora is well-regarded in the industry, brings extensive experience in designing and executing cli

SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate achievements. "Our strategic acquisition of nimacimab in August 2023 has propelled Skye into the metabolic landscape, where there is a need to provide patients with obesity more tolerable and sustainable therapeutic alternatives to manage weight loss and address comorbid conditions," said Punit Dhillon, CEO of Skye. "In Q2, at our event, ‘Metabolic Rewiring wi

SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced the appointment of Karen Smith, MD, Ph.D., MBA, LLM to its Board of Directors. Dr. Smith brings significant global biotech and biopharma leadership experience, complementing the Company's operational and clinical expertise. Our strategic focus on the Nimacimab metabolic program will be supported by an evolving board as Keith Ward, PhD, and Praveen Tyle, PhD, resign from their roles as Boa

SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that the company's third quarter 2024 financial results will be released after market close on Thursday, November 7, 2024. Skye will host a conference call to discuss its results at 1:30 p.m. PT/4:30 p.m. ET. The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Following the call, a replay and transcript will be available at the same website.

8-K - Skye Bioscience, Inc. (0001516551) (Filer)

8-K - Skye Bioscience, Inc. (0001516551) (Filer)

DEF 14A - Skye Bioscience, Inc. (0001516551) (Filer)

PRE 14A - Skye Bioscience, Inc. (0001516551) (Filer)

8-K - Skye Bioscience, Inc. (0001516551) (Filer)

S-8 - Skye Bioscience, Inc. (0001516551) (Filer)

10-Q - Skye Bioscience, Inc. (0001516551) (Filer)

8-K - Skye Bioscience, Inc. (0001516551) (Filer)

8-K - Skye Bioscience, Inc. (0001516551) (Filer)

EFFECT - Skye Bioscience, Inc. (0001516551) (Filer)

Scotiabank initiated coverage of Skye Bioscience with a rating of Sector Outperform and set a new price target of $20.00

JMP Securities initiated coverage of Skye Bioscience with a rating of Mkt Outperform and set a new price target of $15.00

Craig Hallum initiated coverage of Skye Bioscience with a rating of Buy and set a new price target of $18.00

Cantor Fitzgerald initiated coverage of Skye Bioscience with a rating of Overweight and set a new price target of $21.00

Craig-Hallum analyst Albert Lowe initiates coverage on Skye Bioscience (NASDAQ:SKYE) with a Buy rating and announces Price Target of $18.

Cantor Fitzgerald analyst Kristen Kluska reiterates Skye Bioscience (NASDAQ:SKYE) with a Overweight and maintains $14 price target.

Shares of Quantum Corporation (NASDAQ:QMCO) fell sharply during Tuesday's session after the company reported worse-than-expected FY24 financial results and issued FY25 guidance below estimates. Quantum shares dipped 44.5% to $0.43 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Reliance Global Group, Inc. (NASDAQ:RELI) shares jumped 350% to $1.00 after the company issued an update on the pending acquisition of Spetner Associates. NLS Pharmaceutics AG (NASDAQ:NLSP) shares rose 166% to $0.3930 after jumping 30% on Monday. Actelis Networks, Inc. (NASDAQ:ASNS) climbed 80.9% to $2.08 after the company announced a partnership with Carahsoft Tech

Cantor Fitzgerald analyst Kristen Kluska reiterates Skye Bioscience (NASDAQ:SKYE) with a Overweight and maintains $14 price target.

Cantor Fitzgerald analyst Kristen Kluska reiterates Skye Bioscience (NASDAQ:SKYE) with a Overweight and maintains $14 price target.

Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) fell sharply during Monday's session after the company announced its SBI-100 Ophthalmic Emulsion Phase 2a trial did not achieve target product profile and has discontinued the program. Skye Bioscience shares tumbled 18.9% to $8.87 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Big Tree Cloud Holdings Limited (NASDAQ:DSY) shares jumped 123% to $4.3001 following the completion of the company’s business combination with Plutonian Acquisition Corp. and amid continued volatility following its Nasdaq debut last week. KWESST Micro Systems Inc. (NASDAQ:KWE) gained 79.8% to $0.7082 after the company was aw

Gainers Seres Therapeutics (NASDAQ:MCRB) stock moved upwards by 34.0% to $0.82 during Monday's regular session. The company's market cap stands at $124.5 million. Renovaro (NASDAQ:RENB) shares increased by 32.51% to $1.71. The market value of their outstanding shares is at $252.1 million. Champions Oncology (NASDAQ:CSBR) shares increased by 22.82% to $5.65. The company's market cap stands at $76.8 million. Nanoviricides (AMEX:NNVC) stock rose 22.02% to $3.26. The market value of their outstanding shares is at $38.4 million. Semler Scientific (NASDAQ:SMLR) stock moved upwards by 20.13% to $38.0. The market value of their outstanding shares is at $268.5 million. TransCode Therapeutics (N

DSY: 255% | Big Tree Cloud shares are trading higher following the completion of the company's business combination with Plutonian Acquisition Corp. and amid continued volatility following its Nasdaq debut last week. SKYE: -45% | Skye Bioscience shares are trading lower after the company announced its SBI-100 Ophthalmic Emulsion Phase 2a trial did not achieve target product profile and has discontinued the program. KKR: 9% | KKR & Co shares are trading higher after it was announced the company will join the S&P 500.